Astagraf XL + Prograf + Mycophenolate mofetil
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
End Stage Renal Disease
Conditions
End Stage Renal Disease
Trial Timeline
May 1, 2014 → Feb 1, 2015
NCT ID
NCT02221583About Astagraf XL + Prograf + Mycophenolate mofetil
Astagraf XL + Prograf + Mycophenolate mofetil is a approved stage product being developed by Astellas Pharma for End Stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02221583. Target conditions include End Stage Renal Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02221583 | Approved | Completed |
Competing Products
20 competing products in End Stage Renal Disease